{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:41:35Z","timestamp":1793727695131,"version":"4.6.1"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Combination tetrahydrocannabinol (THC)\/cannabidiol (CBD) medicines or CBD-only medicines are prospective treatments for chronic pain, stress, anxiety, depression, and insomnia. THC and CBD increase signaling from cannabinoid receptors, which reduces synaptic transmission in parts of the central and peripheral nervous systems and reduces the secretion of inflammatory factors from immune and glial cells. The overall effect of adding CBD to THC medicines is to enhance the analgesic effect but counteract some of the adverse effects. There is substantial evidence for the effectiveness of THC\/CBD combination medicines for chronic pain, especially neuropathic and nociplastic pain or pain with an inflammatory component. For CBD-only medication, there is substantial evidence for stress, moderate evidence for anxiety and insomnia, and minimal evidence for depression and pain. THC\/CBD combination medicines have a good tolerability and safety profile relative to opioid analgesics and have negligible dependence and abuse potential; however, should be avoided in patients predisposed to depression, psychosis and suicide as these conditions appear to be exacerbated. Non-serious adverse events are usually dose-proportional, subject to tachyphylaxis and are rarely dose limiting when patients are commenced on a low dose with gradual up-titration. THC and CBD inhibit several Phase I and II metabolism enzymes, which increases the exposure to a wide range of drugs and appropriate care needs to be taken. Low-dose CBD that appears effective for chronic pain and mental health has good tolerability and safety, with few adverse effects and is appropriate as an initial treatment.<\/jats:p>","DOI":"10.1007\/s10787-022-01020-z","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T09:11:23Z","timestamp":1657185083000},"page":"1167-1178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1594-9310","authenticated-orcid":false,"given":"Jeremy D.","family":"Henson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7490-9298","authenticated-orcid":false,"given":"Luis","family":"Vitetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0090-7895","authenticated-orcid":false,"given":"Sean","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"1020_CR1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000521492","volume":"5","author":"S Abelev","year":"2022","unstructured":"Abelev S, Warne LN, Benson M, Hardy M, Nayee S, Barlow J (2022) Medicinal cannabis for the treatment of chronic refractory pain: an investigation of the adverse event profile and health-related quality of life impact of an oral formulation. Med Cannabis Cannabinoids 5:20\u201331","journal-title":"Med Cannabis Cannabinoids"},{"key":"1020_CR2","unstructured":"ACMD (2020) Cannabis-based products for medicinal use (CBPMs) in humans. London: Home Office, pp 1\u201348"},{"key":"1020_CR3","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/nn1916","volume":"10","author":"N Agarwal","year":"2007","unstructured":"Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10:870\u2013879","journal-title":"Nat Neurosci"},{"key":"1020_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2021.105876","volume":"210","author":"C Amaral","year":"2021","unstructured":"Amaral C, Trouille FM, Almeida CF, Correia-Da-silva G, Teixeira N (2021) Unveiling the mechanism of action behind the anti-cancer properties of cannabinoids in ER(+) breast cancer cells: Impact on aromatase and steroid receptors. J Steroid Biochem Mol Biol 210:105876","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1020_CR5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Washington D. C","edition":"5"},{"key":"1020_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00213-019-05442-6","volume":"237","author":"E Appiah-Kusi","year":"2020","unstructured":"Appiah-Kusi E, Petros N, Wilson R, Colizzi M, Bossong MG, Valmaggia L, Mondelli V, McGuire P, Bhattacharyya S (2020) Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology 237:1121\u20131130","journal-title":"Psychopharmacology"},{"key":"1020_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e536","volume":"344","author":"M Asbridge","year":"2012","unstructured":"Asbridge M, Hayden JA, Cartwright JL (2012) Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 344:e536","journal-title":"BMJ"},{"key":"1020_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","volume":"172","author":"S Babalonis","year":"2017","unstructured":"Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, Walsh SL (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172:9\u201313","journal-title":"Drug Alcohol Depend"},{"key":"1020_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11920-017-0775-9","volume":"19","author":"KA Babson","year":"2017","unstructured":"Babson KA, Sottile J, Morabito D (2017) Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep 19:23","journal-title":"Curr Psychiatry Rep"},{"issue":"9","key":"1020_CR10","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.3390\/cancers12092447","volume":"12","author":"G Bar-Sela","year":"2020","unstructured":"Bar-Sela G, Cohen I, Campisi-Pinto S, Lewitus GM, Oz-Ari L, Jehassi A, Peer A, Turgeman I, Vernicova O, Berman P, Wollner M, Moskovitz M, Meiri D (2020) Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome. Cancers 12(9):2447","journal-title":"Cancers"},{"key":"1020_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/can.2017.0047","volume":"3","author":"C Beale","year":"2018","unstructured":"Beale C, Broyd SJ, Chye Y, Suo C, Schira M, Galettis P, Martin JH, Y\u00fccel M, Solowij N (2018) Prolonged cannabidiol treatment effects on hippocampal subfield volumes in current cannabis users. Cannabis Cannabinoid Res 3:94\u2013107","journal-title":"Cannabis Cannabinoid Res"},{"key":"1020_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157488611798280924","volume":"6","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 6:237\u2013249","journal-title":"Curr Drug Saf"},{"key":"1020_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s42238-021-00073-1","volume":"3","author":"A Bhaskar","year":"2021","unstructured":"Bhaskar A, Bell A, Boivin M, Briques W, Brown M, Clarke H, Cyr C, Eisenberg E, de Oliveira Silva RF, Frohlich E, Georgius P, Hogg M, Horsted TI, Maccallum CA, M\u00fcller-Vahl KR, O\u2019connell C, Sealey R, Seibolt M, Sihota A, Smith BK, Sulak D, Vigano A, Moulin DE (2021) Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. J Cannabis Res 3:22","journal-title":"J Cannabis Res"},{"key":"1020_CR14","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","volume":"12","author":"EM Blessing","year":"2015","unstructured":"Blessing EM, Steenkamp MM, Manzanares J, Marmar CR (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12:825\u2013836","journal-title":"Neurotherapeutics"},{"key":"1020_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1377\/hlthaff.2018.05266","volume":"38","author":"KF Boehnke","year":"2019","unstructured":"Boehnke KF, Gangopadhyay S, Clauw DJ, Haffajee RL (2019) Qualifying conditions of medical cannabis license holders in the United States. Health Aff (millwood) 38:295\u2013302","journal-title":"Health Aff (millwood)"},{"key":"1020_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","volume":"74","author":"S Bonaccorso","year":"2019","unstructured":"Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F (2019) Cannabidiol (CBD) use in psychiatric disorders: a systematic review. Neurotoxicology 74:282\u2013298","journal-title":"Neurotoxicology"},{"key":"1020_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/phar.1187","volume":"33","author":"LM Borgelt","year":"2013","unstructured":"Borgelt LM, Franson KL, Nussbaum AM, Wang GS (2013) The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 33:195\u2013209","journal-title":"Pharmacotherapy"},{"key":"1020_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00213-020-05712-8","volume":"238","author":"SC Britch","year":"2021","unstructured":"Britch SC, Babalonis S, Walsh SL (2021) Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology 238:9\u201328","journal-title":"Psychopharmacology"},{"issue":"4","key":"1020_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3390\/jcm9040919","volume":"9","author":"JD Brown","year":"2020","unstructured":"Brown JD (2020) Potential adverse drug events with tetrahydrocannabinol (THC) due to drug-drug interactions. J Clin Med 9(4):919","journal-title":"J Clin Med"},{"issue":"7","key":"1020_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/jcm8070989","volume":"8","author":"JD Brown","year":"2019","unstructured":"Brown JD, Winterstein AG (2019) Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med 8(7):989","journal-title":"J Clin Med"},{"key":"1020_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/02791072.1998.10399689","volume":"30","author":"SR Calhoun","year":"1998","unstructured":"Calhoun SR, Galloway GP, Smith DE (1998) Abuse potential of dronabinol (Marinol). J Psychoactive Drugs 30:187\u2013196","journal-title":"J Psychoactive Drugs"},{"key":"1020_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00213-008-1168-x","volume":"199","author":"AC Campos","year":"2008","unstructured":"Campos AC, Guimar\u00e3es FS (2008) Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology 199:223\u2013230","journal-title":"Psychopharmacology"},{"key":"1020_CR23","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1017\/S1461145712001502","volume":"16","author":"AC Campos","year":"2013","unstructured":"Campos AC, Ortega Z, Palazuelos J, Foga\u00e7a MV, Aguiar DC, D\u00edaz-Alonso J, Ortega-Guti\u00e9rrez S, V\u00e1zquez-Villa H, Moreira FA, Guzm\u00e1n M, Galve-Roperh I, Guimar\u00e3es FS (2013) The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol 16:1407\u20131419","journal-title":"Int J Neuropsychopharmacol"},{"key":"1020_CR24","doi-asserted-by":"publisher","first-page":"417s","DOI":"10.1002\/j.1552-4604.1981.tb02622.x","volume":"21","author":"EA Carlini","year":"1981","unstructured":"Carlini EA, Cunha JM (1981) Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 21:417s\u2013427s","journal-title":"J Clin Pharmacol"},{"key":"1020_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/can.2018.0006","volume":"3","author":"J Corroon","year":"2018","unstructured":"Corroon J, Phillips JA (2018) A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res 3:152\u2013161","journal-title":"Cannabis Cannabinoid Res"},{"key":"1020_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/sj.bjp.0705920","volume":"143","author":"B Costa","year":"2004","unstructured":"Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M (2004) Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 143:247\u2013250","journal-title":"Br J Pharmacol"},{"key":"1020_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejphar.2006.11.006","volume":"556","author":"B Costa","year":"2007","unstructured":"Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M (2007) The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 556:75\u201383","journal-title":"Eur J Pharmacol"},{"key":"1020_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","volume":"25","author":"JA Crippa","year":"2011","unstructured":"Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Sim\u00f5es MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, Santos Filho A, Freitas-Ferrari MC, McGuire PK, Zuardi AW, Busatto GF, Hallak JE (2011) Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 25:121\u2013130","journal-title":"J Psychopharmacol"},{"key":"1020_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.npp.1300340","volume":"29","author":"JA Crippa","year":"2004","unstructured":"Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JE, McGuire PK, Filho Busatto G (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29:417\u2013426","journal-title":"Neuropsychopharmacology"},{"key":"1020_CR30","doi-asserted-by":"publisher","first-page":"e2120603","DOI":"10.1001\/jamanetworkopen.2021.20603","volume":"4","author":"JAS Crippa","year":"2021","unstructured":"Crippa JAS, Zuardi AW, Guimar\u00e3es FS, Campos AC, de Limaos\u00f3rio F, Loureiro SR, Dossantos RG, Souza JDS, Ushirohira JM, Pacheco JC, Ferreira RR, Mancinicosta KC, Scomparin DS, Scarante FF, Pires-Dos-santos I, Mechoulam R, Kapczinski F, Fonseca BAL, Esposito DLA, Pereira-Lima K, Sen S, Andraus MH, Hallak JEC (2021) Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during the COVID-19 pandemic: a randomized clinical trial. JAMA Netw Open 4:e2120603","journal-title":"JAMA Netw Open"},{"key":"1020_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00213-012-2955-y","volume":"226","author":"RK Das","year":"2013","unstructured":"Das RK, Kamboj SK, Ramadas M, Yogan K, Gupta V, Redman E, Curran HV, Morgan CJ (2013) Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology 226:781\u2013792","journal-title":"Psychopharmacology"},{"key":"1020_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/01.jcp.0000106222.36344.96","volume":"24","author":"J Davidson","year":"2004","unstructured":"Davidson J, Yaryura-Tobias J, Dupont R, Stallings L, Barbato LM, van der Hoop RG, Li D (2004) Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24:118\u2013125","journal-title":"J Clin Psychopharmacol"},{"key":"1020_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.682","volume":"8","author":"DL de Almeida","year":"2020","unstructured":"de Almeida DL, Devi LA (2020) Diversity of molecular targets and signaling pathways for CBD. Pharmacol Res Perspect 8:e00682","journal-title":"Pharmacol Res Perspect"},{"key":"1020_CR34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/j.pain.0000000000001386","volume":"160","author":"D de Gregorio","year":"2019","unstructured":"de Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M, Aboud M, Maione S, Comai S, Gobbi G (2019) Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain 160:136\u2013150","journal-title":"Pain"},{"key":"1020_CR35","volume":"9","author":"R Desai","year":"2017","unstructured":"Desai R, Patel U, Sharma S, Amin P, Bhuva R, Patel MS, Sharma N, Shah M, Patel S, Savani S, Batra N, Kumar G (2017) Recreational marijuana use and acute myocardial infarction: insights from nationwide inpatient sample in the United States. Cureus 9:e1816","journal-title":"Cureus"},{"key":"1020_CR36","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/ejn.12455","volume":"39","author":"I Devesa","year":"2014","unstructured":"Devesa I, Ferrer-Montiel A (2014) Neurotrophins, endocannabinoids and thermo-transient receptor potential: a threesome in pain signalling. Eur J Neurosci 39:353\u2013362","journal-title":"Eur J Neurosci"},{"key":"1020_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105357","volume":"164","author":"M di Bartolomeo","year":"2021","unstructured":"di Bartolomeo M, Stark T, Maurel OM, Iannotti FA, Kuchar M, Ruda-Kucerova J, Piscitelli F, Laudani S, Pekarik V, Salomone S, Arosio B, Mechoulam R, Maccarrone M, Drago F, Wotjak CT, di Marzo V, Vismara M, Dell\u2019Osso B, D\u2019Addario C, Micale V (2021) Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: analyses in patients and in perinatal \u03949-tetrahydrocannabinol-exposed rats. Pharmacol Res 164:105357","journal-title":"Pharmacol Res"},{"key":"1020_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fncel.2018.00035","volume":"12","author":"OC Eller-Smith","year":"2018","unstructured":"Eller-Smith OC, Nicol AL, Christianson JA (2018) Potential mechanisms underlying centralized pain and emerging therapeutic interventions. Front Cell Neurosci 12:35","journal-title":"Front Cell Neurosci"},{"key":"1020_CR39","doi-asserted-by":"publisher","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","volume":"290","author":"MW Elmes","year":"2015","unstructured":"Elmes MW, Kaczocha M, Berger WT, Leung K, Ralph BP, Wang L, Sweeney JM, Miyauchi JT, Tsirka SE, Ojima I, Deutsch DG (2015) Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem 290:8711\u20138721","journal-title":"J Biol Chem"},{"key":"1020_CR40","doi-asserted-by":"publisher","DOI":"10.1089\/can.2021.0145","author":"M Ergisi","year":"2022","unstructured":"Ergisi M, Erridge S, Harris M, Kawka M, Nimalan D, Salazar O, Loupasaki K, Ali R, Holvey C, Coomber R, Usmani A, Sajad M, Beri S, Hoare J, Khan SA, Weatherall MW, Platt M, Rucker JJ, Sodergren MH (2022) An updated analysis of clinical outcome measures across patients from the UK medical cannabis registry. Cannabis Cannabinoid Res. https:\/\/doi.org\/10.1089\/can.2021.0145","journal-title":"Cannabis Cannabinoid Res"},{"key":"1020_CR41","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/phar.1780","volume":"36","author":"PS Fasinu","year":"2016","unstructured":"Fasinu PS, Phillips S, Elsohly MA, Walker LA (2016) Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy 36:781\u2013796","journal-title":"Pharmacotherapy"},{"key":"1020_CR42","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s40265-021-01602-1","volume":"81","author":"MA Fitzcharles","year":"2021","unstructured":"Fitzcharles MA, Petzke F, T\u00f6lle TR, H\u00e4user W (2021) Cannabis-based medicines and medical cannabis in the treatment of nociplastic pain. Drugs 81:2103\u20132116","journal-title":"Drugs"},{"key":"1020_CR43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neuropharm.2018.03.001","volume":"135","author":"MV Foga\u00e7a","year":"2018","unstructured":"Foga\u00e7a MV, Campos AC, Coelho LD, Duman RS, Guimar\u00e3es FS (2018) The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: Role of neurogenesis and dendritic remodeling. Neuropharmacology 135:22\u201333","journal-title":"Neuropharmacology"},{"key":"1020_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s43032-021-00588-1","author":"BM Fonseca","year":"2021","unstructured":"Fonseca BM, Rebelo I (2021) Cannabis and cannabinoids in reproduction and fertility: where we stand. Reprod Sci. https:\/\/doi.org\/10.1007\/s43032-021-00588-1","journal-title":"Reprod Sci"},{"key":"1020_CR45","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1185\/030079906X132488","volume":"22","author":"R Freynhagen","year":"2006","unstructured":"Freynhagen R, Baron R, Gockel U, T\u00f6lle TR (2006) painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 22:1911\u20131920","journal-title":"Curr Med Res Opin"},{"key":"1020_CR46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/ALN.0b013e3181a51e0d","volume":"111","author":"S Furuse","year":"2009","unstructured":"Furuse S, Kawamata T, Yamamoto J, Niiyama Y, Omote K, Watanabe M, Namiki A (2009) Reduction of bone cancer pain by activation of spinal cannabinoid receptor 1 and its expression in the superficial dorsal horn of the spinal cord in a murine model of bone cancer pain. Anesthesiology 111:173\u2013186","journal-title":"Anesthesiology"},{"key":"1020_CR47","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/sj.npp.1301252","volume":"32","author":"B Garc\u00eda-Bueno","year":"2007","unstructured":"Garc\u00eda-Bueno B, Caso JR, P\u00e9rez-Nievas BG, Lorenzo P, Leza JC (2007) Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats. Neuropsychopharmacology 32:1251\u20131260","journal-title":"Neuropsychopharmacology"},{"key":"1020_CR48","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1476-5381.2011.01625.x","volume":"165","author":"MS Garc\u00eda-Guti\u00e9rrez","year":"2012","unstructured":"Garc\u00eda-Guti\u00e9rrez MS, Garc\u00eda-Bueno B, Zoppi S, Leza JC, Manzanares J (2012) Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors. Br J Pharmacol 165:951\u2013964","journal-title":"Br J Pharmacol"},{"key":"1020_CR49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/jat\/bks081","volume":"37","author":"DA Gorelick","year":"2013","unstructured":"Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, McMahon RP, Liu F, Ortemann-Renon C, Bonnet D, Huestis MA (2013) Tolerance to effects of high-dose oral \u03b49-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers. J Anal Toxicol 37:11\u201316","journal-title":"J Anal Toxicol"},{"key":"1020_CR50","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/BF02244012","volume":"100","author":"FS Guimar\u00e3es","year":"1990","unstructured":"Guimar\u00e3es FS, Chiaretti TM, Graeff FG, Zuardi AW (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100:558\u2013559","journal-title":"Psychopharmacology"},{"key":"1020_CR51","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen20X101010","author":"G Gulbransen","year":"2020","unstructured":"Gulbransen G, Xu W, Arroll B (2020) Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open. https:\/\/doi.org\/10.3399\/bjgpopen20X101010","journal-title":"BJGP Open"},{"key":"1020_CR52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1300\/J175v03n03_03","volume":"3","author":"GW Guy","year":"2004","unstructured":"Guy GW, Flint ME (2004) A single centre, placebo-controlled, four period, crossover, tolerability study assessing, pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of cannabis based medicine extracts (CBMEs) (GWPD9901), plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a cannabis based medicine extract given via two administration routes (GWPD9901 EXT). J Cannabis Ther 3:35\u201377","journal-title":"J Cannabis Ther"},{"key":"1020_CR53","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1161\/STROKEAHA.115.008680","volume":"46","author":"DG Hackam","year":"2015","unstructured":"Hackam DG (2015) Cannabis and stroke: systematic appraisal of case reports. Stroke 46:852\u2013856","journal-title":"Stroke"},{"issue":"24","key":"1020_CR54","doi-asserted-by":"publisher","first-page":"5852","DOI":"10.3390\/jcm10245852","volume":"10","author":"JD Henson","year":"2021","unstructured":"Henson JD, Vitetta L, Quezada M, Hall S (2021) Enhancing endocannabinoid control of stress with cannabidiol. J Clin Med 10(24):5852","journal-title":"J Clin Med"},{"key":"1020_CR55","first-page":"1","volume":"7","author":"CJ Hillard","year":"2016","unstructured":"Hillard CJ, Beatka M, Sarvaideo J (2016) Endocannabinoid signaling and the hypothalamic-pituitary-adrenal axis. Compr Physiol 7:1\u201315","journal-title":"Compr Physiol"},{"key":"1020_CR56","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.euroneuro.2014.11.014","volume":"25","author":"C Hindocha","year":"2015","unstructured":"Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ, Curran HV (2015) Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 25:325\u2013334","journal-title":"Eur Neuropsychopharmacol"},{"key":"1020_CR57","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1212\/WNL.0b013e318212ab0c","volume":"76","author":"K Honarmand","year":"2011","unstructured":"Honarmand K, Tierney MC, O\u2019Connor P, Feinstein A (2011) Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology 76:1153\u20131160","journal-title":"Neurology"},{"key":"1020_CR58","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/cbdv.200790152","volume":"4","author":"MA Huestis","year":"2007","unstructured":"Huestis MA (2007) Human cannabinoid pharmacokinetics. Chem Biodivers 4:1770\u20131804","journal-title":"Chem Biodivers"},{"key":"1020_CR59","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","volume":"2","author":"K Iffland","year":"2017","unstructured":"Iffland K, Grotenhermen F (2017) An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2:139\u2013154","journal-title":"Cannabis Cannabinoid Res"},{"key":"1020_CR60","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","volume":"39","author":"JR Johnson","year":"2010","unstructured":"Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39:167\u2013179","journal-title":"J Pain Symptom Manage"},{"key":"1020_CR61","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/0014-2999(74)90129-0","volume":"28","author":"IG Karniol","year":"1974","unstructured":"Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974) Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J Pharmacol 28:172\u2013177","journal-title":"Eur J Pharmacol"},{"key":"1020_CR62","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617\u2013627","journal-title":"Arch Gen Psychiatry"},{"key":"1020_CR63","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1097\/j.pain.0000000000002324","volume":"162","author":"E Kosek","year":"2021","unstructured":"Kosek E, Clauw D, Nijs J, Baron R, Gilron I, Harris RE, Mico JA, Rice ASC, Sterling M (2021) Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. Pain 162:2629\u20132634","journal-title":"Pain"},{"key":"1020_CR64","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172:4790\u20134805","journal-title":"Br J Pharmacol"},{"key":"1020_CR65","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1111\/bph.13724","volume":"174","author":"JLC Lee","year":"2017","unstructured":"Lee JLC, Bertoglio LJ, Guimar\u00e3es FS, Stevenson CW (2017) Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br J Pharmacol 174:3242\u20133256","journal-title":"Br J Pharmacol"},{"key":"1020_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterk\u00f6tter J, Hellmich M, Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94","journal-title":"Transl Psychiatry"},{"key":"1020_CR67","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4088\/JCP.v66n0213","volume":"66","author":"MR Liebowitz","year":"2005","unstructured":"Liebowitz MR, Mangano RM, Bradwejn J, Asnis G (2005) A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 66:238\u2013247","journal-title":"J Clin Psychiatry"},{"key":"1020_CR68","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fphar.2018.00315","volume":"9","author":"IMP Linares","year":"2018","unstructured":"Linares IMP, Guimaraes FS, Eckeli A, Crippa ACS, Zuardi AW, Souza JDS, Hallak JE, Crippa JAS (2018) No acute effects of cannabidiol on the sleep-wake cycle of healthy subjects: a randomized, double-blind, placebo-controlled crossover study. Front Pharmacol 9:315","journal-title":"Front Pharmacol"},{"key":"1020_CR69","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","volume":"84","author":"CJ Lucas","year":"2018","unstructured":"Lucas CJ, Galettis P, Schneider J (2018) The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 84:2477\u20132482","journal-title":"Br J Clin Pharmacol"},{"key":"1020_CR70","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1089\/can.2019.0037","volume":"4","author":"S Lunn","year":"2019","unstructured":"Lunn S, Diaz P, O\u2019Hearn S, Cahill SP, Blake A, Narine K, Dyck JRB (2019) Human pharmacokinetic parameters of orally administered \u0394(9)-tetrahydrocannabinol capsules are altered by fed versus fasted conditions and sex differences. Cannabis Cannabinoid Res 4:255\u2013264","journal-title":"Cannabis Cannabinoid Res"},{"key":"1020_CR71","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-26573-2_10","author":"K Mackie","year":"2005","unstructured":"Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol. https:\/\/doi.org\/10.1007\/3-540-26573-2_10","journal-title":"Handb Exp Pharmacol"},{"key":"1020_CR72","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bcp.2018.09.013","volume":"157","author":"J Manzanares","year":"2018","unstructured":"Manzanares J, Caba\u00f1ero D, Puente N, Garc\u00eda-Guti\u00e9rrez MS, Grandes P, Maldonado R (2018) Role of the endocannabinoid system in drug addiction. Biochem Pharmacol 157:108\u2013121","journal-title":"Biochem Pharmacol"},{"key":"1020_CR73","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3389\/fphar.2017.00744","volume":"8","author":"E Mart\u00ednez-Pinilla","year":"2017","unstructured":"Mart\u00ednez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, Vincenzi F, Ferreiro-Vera C, Oyarzabal J, Canela EI, Lanciego JL, Nadal X, Navarro G, Borea PA, Franco R (2017) Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB(2) receptors. Front Pharmacol 8:744","journal-title":"Front Pharmacol"},{"key":"1020_CR74","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3389\/fpsyg.2019.02466","volume":"10","author":"MASATAKA, N.","year":"2019","unstructured":"MASATAKA, N. (2019) Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front Psychol 10:2466","journal-title":"Front Psychol"},{"key":"1020_CR75","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.12944","volume":"172","author":"JM McPartland","year":"2015","unstructured":"McPartland JM, Duncan M, di Marzo V, Pertwee RG (2015) Are cannabidiol and \u0394(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172:737\u2013753","journal-title":"Br J Pharmacol"},{"key":"1020_CR76","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","volume":"9","author":"SA Millar","year":"2018","unstructured":"Millar SA, Stone NL, Yates AS, O\u2019Sullivan SE (2018) A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol 9:1365","journal-title":"Front Pharmacol"},{"key":"1020_CR77","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s42238-021-00061-5","volume":"3","author":"J Moltke","year":"2021","unstructured":"Moltke J, Hindocha C (2021) Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. J Cannabis Res 3:5","journal-title":"J Cannabis Res"},{"key":"1020_CR78","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/npp.2015.166","volume":"41","author":"M Morena","year":"2016","unstructured":"Morena M, Patel S, Bains JS, Hill MN (2016) Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology 41:80\u2013102","journal-title":"Neuropsychopharmacology"},{"key":"1020_CR79","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(11)60750-2","volume":"379","author":"CM Morin","year":"2012","unstructured":"Morin CM, Benca R (2012) Chronic insomnia. Lancet 379:1129\u20131141","journal-title":"Lancet"},{"key":"1020_CR80","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1089\/bfm.2017.0020","volume":"12","author":"J Mourh","year":"2017","unstructured":"Mourh J, Rowe H (2017) Marijuana and breastfeeding: applicability of the current literature to clinical practice. Breastfeed Med 12:582\u2013596","journal-title":"Breastfeed Med"},{"issue":"12","key":"1020_CR81","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.3390\/molecules26123573","volume":"26","author":"K Mozaffari","year":"2021","unstructured":"Mozaffari K, Willette S, Lucker BF, Kovar SE, Holguin FO, Guzman I (2021) The effects of food on cannabidiol bioaccessibility. Molecules 26(12):3573","journal-title":"Molecules"},{"key":"1020_CR82","first-page":"012182","volume":"3","author":"M M\u00fccke","year":"2018","unstructured":"M\u00fccke M, Phillips T, Radbruch L, Petzke F, H\u00e4user W (2018) Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 3:012182","journal-title":"Cochrane Database Syst Rev"},{"key":"1020_CR83","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s10620-017-4540-z","volume":"62","author":"T Naftali","year":"2017","unstructured":"Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M, Laish I, Benjaminov F, Konikoff FM (2017) Low-Dose Cannabidiol is safe but not effective in the treatment for crohn\u2019s disease, a randomized controlled trial. Dig Dis Sci 62:1615\u20131620","journal-title":"Dig Dis Sci"},{"key":"1020_CR84","volume-title":"The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research","author":"National Academies of Sciences, Engineering, and medicine","year":"2017","unstructured":"National Academies of Sciences, Engineering, and medicine (2017) The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. The National Academies Press, Washington DC"},{"key":"1020_CR85","unstructured":"National Institute for Health And Care Excellence (NICE) Guidelines Updates Team (2019) Cannabis-based medicinal products; [B] evidence review for chronic pain. NG144. pp 1\u2013256"},{"key":"1020_CR86","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1352458511419700","volume":"18","author":"W Notcutt","year":"2012","unstructured":"Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R (2012) A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex\u00ae (nabiximols). Mult Scler 18:219\u2013228","journal-title":"Mult Scler"},{"key":"1020_CR87","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1365-2044.2004.03674.x","volume":"59","author":"W Notcutt","year":"2004","unstructured":"Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C (2004) Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 \u201cN of 1\u201d studies. Anaesthesia 59:440\u2013452","journal-title":"Anaesthesia"},{"key":"1020_CR88","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/bms.1200130206","volume":"13","author":"A Ohlsson","year":"1986","unstructured":"Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE (1986) Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom 13:77\u201383","journal-title":"Biomed Environ Mass Spectrom"},{"key":"1020_CR89","first-page":"1002","volume":"253","author":"ES Onaivi","year":"1990","unstructured":"Onaivi ES, Green MR, Martin BR (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253:1002\u20131009","journal-title":"J Pharmacol Exp Ther"},{"key":"1020_CR90","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11920-019-1026-z","volume":"21","author":"EP Papagianni","year":"2019","unstructured":"Papagianni EP, Stevenson CW (2019) Cannabinoid regulation of fear and anxiety: an update. Curr Psychiatry Rep 21:38","journal-title":"Curr Psychiatry Rep"},{"key":"1020_CR91","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG (2008a) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:199\u2013215","journal-title":"Br J Pharmacol"},{"key":"1020_CR92","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1369-1600.2008.00108.x","volume":"13","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG (2008b) Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 13:147\u2013159","journal-title":"Addict Biol"},{"key":"1020_CR93","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/14737175.2021.1935879","volume":"21","author":"JM Prieto Gonz\u00e1lez","year":"2021","unstructured":"Prieto Gonz\u00e1lez JM, Vila Silv\u00e1n C (2021) Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years accumulated evidence from clinical trials. Expert Rev Neurother 21:755\u2013778","journal-title":"Expert Rev Neurother"},{"key":"1020_CR94","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1517\/14740338.2011.575778","volume":"10","author":"ROBSON, P.","year":"2011","unstructured":"ROBSON, P. (2011) Abuse potential and psychoactive effects of \u03b4-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 10:675\u2013685","journal-title":"Expert Opin Drug Saf"},{"key":"1020_CR95","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/pm\/pnz227","volume":"20","author":"EB Russo","year":"2019","unstructured":"Russo EB (2019) Cannabis and pain. Pain Med 20:2083\u20132085","journal-title":"Pain Med"},{"key":"1020_CR96","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1177\/0269881120926677","volume":"34","author":"AK Schlag","year":"2020","unstructured":"Schlag AK, Baldwin DS, Barnes M, Bazire S, Coathup R, Curran HV, McShane R, Phillips LD, Singh I, Nutt DJ (2020) Medical cannabis in the UK: from principle to practice. J Psychopharmacol 34:931\u2013937","journal-title":"J Psychopharmacol"},{"key":"1020_CR97","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/hup.1196","volume":"26","author":"KA Schoedel","year":"2011","unstructured":"Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM (2011) A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol 26:224\u2013236","journal-title":"Hum Psychopharmacol"},{"key":"1020_CR98","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.yebeh.2018.07.027","volume":"88","author":"KA Schoedel","year":"2018","unstructured":"Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, Etges T, Sommerville K (2018) Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: a randomized, double-blind, controlled trial. Epilepsy Behav 88:162\u2013171","journal-title":"Epilepsy Behav"},{"key":"1020_CR99","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7812\/TPP\/18-041","volume":"23","author":"S Shannon","year":"2019","unstructured":"Shannon S, Lewis N, Lee H, Hughes S (2019) Cannabidiol in anxiety and sleep: a large case series. Perm J 23:18\u2013041","journal-title":"Perm J"},{"key":"1020_CR100","doi-asserted-by":"publisher","first-page":"16","DOI":"10.7812\/TPP\/16-005","volume":"20","author":"S Shannon","year":"2016","unstructured":"Shannon S, Opila-Lehman J (2016) Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Perm J 20:16\u2013005","journal-title":"Perm J"},{"key":"1020_CR101","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/phar.2512","volume":"41","author":"LH Silmore","year":"2021","unstructured":"Silmore LH, Willmer AR, Capparelli EV, Rosania GR (2021) Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: a systematic review of clinical studies. Pharmacotherapy 41:405\u2013420","journal-title":"Pharmacotherapy"},{"key":"1020_CR102","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40119-017-0102-x","volume":"7","author":"A Singh","year":"2018","unstructured":"Singh A, Saluja S, Kumar A, Agrawal S, Thind M, Nanda S, Shirani J (2018) Cardiovascular complications of marijuana and related substances: a review. Cardiol Ther 7:45\u201359","journal-title":"Cardiol Ther"},{"key":"1020_CR103","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.neuroscience.2016.06.006","volume":"338","author":"KA Sluka","year":"2016","unstructured":"Sluka KA, Clauw DJ (2016) Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience 338:114\u2013129","journal-title":"Neuroscience"},{"key":"1020_CR104","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/can.2017.0043","volume":"3","author":"N Solowij","year":"2018","unstructured":"Solowij N, Broyd SJ, Beale C, Prick JA, Greenwood LM, van Hell H, Suo C, Galettis P, Pai N, Fu S, Croft RJ, Martin JH, Y\u00fccel M (2018) Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Res 3:21\u201334","journal-title":"Cannabis Cannabinoid Res"},{"key":"1020_CR105","doi-asserted-by":"publisher","first-page":"105938","DOI":"10.1016\/j.phrs.2021.105938","volume":"174","author":"T Stark","year":"2021","unstructured":"Stark T, Di Martino S, Drago F, Wotjak CT, Micale V (2021) Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment. Pharmacol Res 174:105938","journal-title":"Pharmacol Res"},{"key":"1020_CR106","unstructured":"Statista (2020) Medical cannabis in the United Kingdom (UK). did-71493-1: pp 1\u201332"},{"key":"1020_CR107","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1001\/jama.280.8.708","volume":"280","author":"MB Stein","year":"1998","unstructured":"Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I (1998) Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 280:708\u2013713","journal-title":"JAMA"},{"key":"1020_CR108","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00228-012-1393-4","volume":"69","author":"CG Stott","year":"2013","unstructured":"Stott CG, White L, Wright S, Wilbraham D, Guy GW (2013) A phase I study to assess the effect of food on the single dose bioavailability of the THC\/CBD oromucosal spray. Eur J Clin Pharmacol 69:825\u2013834","journal-title":"Eur J Clin Pharmacol"},{"key":"1020_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109504","volume":"120","author":"J Sun","year":"2019","unstructured":"Sun J, Zhou YQ, Chen SP, Wang XM, Xu BY, Li DY, Tian YK, Ye DW (2019) The endocannabinoid system: Novel targets for treating cancer induced bone pain. Biomed Pharmacother 120:109504","journal-title":"Biomed Pharmacother"},{"key":"1020_CR110","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1634\/theoncologist.2018-0383","volume":"24","author":"T Taha","year":"2019","unstructured":"Taha T, Meiri D, Talhamy S, Wollner M, Peer A, Bar-Sela G (2019) Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. Oncologist 24:549\u2013554","journal-title":"Oncologist"},{"key":"1020_CR111","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/jcph.1412","volume":"59","author":"L Taylor","year":"2019","unstructured":"Taylor L, Crockett J, Tayo B, Morrison G (2019) A phase 1, open-label, parallel-group, single-dose trial of the pharmacokinetics and safety of cannabidiol (CBD) in subjects with mild to severe hepatic impairment. J Clin Pharmacol 59:1110\u20131119","journal-title":"J Clin Pharmacol"},{"key":"1020_CR112","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","volume":"32","author":"L Taylor","year":"2018","unstructured":"Taylor L, Gidal B, Blakey G, Tayo B, Morrison G (2018) A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 32:1053\u20131067","journal-title":"CNS Drugs"},{"key":"1020_CR113","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.amjcard.2013.09.042","volume":"113","author":"G Thomas","year":"2014","unstructured":"Thomas G, Kloner RA, Rezkalla S (2014) Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol 113:187\u2013190","journal-title":"Am J Cardiol"},{"key":"1020_CR114","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.3485","volume":"1","author":"MC Torres-Moreno","year":"2018","unstructured":"Torres-Moreno MC, Papaseit E, Torrens M, Farr\u00e9 M (2018) Assessment of efficacy and tolerability of medicinal cannabinoids in patients with multiple sclerosis: a systematic review and meta-analysis. JAMA Netw Open 1:e183485","journal-title":"JAMA Netw Open"},{"key":"1020_CR115","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2147\/JPR.S192174","volume":"12","author":"MA Ueberall","year":"2019","unstructured":"Ueberall MA, Essner U, Mueller-Schwefe GH (2019) Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German pain e-registry. J Pain Res 12:1577\u20131604","journal-title":"J Pain Res"},{"key":"1020_CR116","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1176\/appi.ajp.158.2.275","volume":"158","author":"MA van Ameringen","year":"2001","unstructured":"van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, Johnston DG, Lavallee YJ, Nandy S, Pecknold JC, Hadrava V, Swinson RP (2001) Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 158:275\u2013281","journal-title":"Am J Psychiatry"},{"key":"1020_CR117","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0091-3057(76)90236-7","volume":"4","author":"RM Vardaris","year":"1976","unstructured":"Vardaris RM, Weisz DJ, Fazel A, Rawitch AB (1976) Chronic administration of delta-9-tetrahydrocannabinol to pregnant rats: studies of pup behavior and placental transfer. Pharmacol Biochem Behav 4:249\u2013254","journal-title":"Pharmacol Biochem Behav"},{"key":"1020_CR118","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1476-5381.2010.00790.x","volume":"160","author":"LK Vaughn","year":"2010","unstructured":"Vaughn LK, Denning G, Stuhr KL, de Wit H, Hill MN, Hillard CJ (2010) Endocannabinoid signalling: has it got rhythm? Br J Pharmacol 160:530\u2013543","journal-title":"Br J Pharmacol"},{"key":"1020_CR119","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s10787-021-00859-y","volume":"29","author":"L Vitetta","year":"2021","unstructured":"Vitetta L, Butcher B, Henson JD, Rutolo D, Hall S (2021) A pilot safety, tolerability and pharmacokinetic study of an oro-buccal administered cannabidiol-dominant anti-inflammatory formulation in healthy individuals: a randomized placebo-controlled single-blinded study. Inflammopharmacology 29:1361\u20131370","journal-title":"Inflammopharmacology"},{"key":"1020_CR120","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1177\/0269881118805495","volume":"32","author":"A Viudez-Mart\u00ednez","year":"2018","unstructured":"Viudez-Mart\u00ednez A, Garc\u00eda-Guti\u00e9rrez MS, Manzanares J (2018) Cannabidiol regulates the expression of hypothalamus-pituitary-adrenal axis-related genes in response to acute restraint stress. J Psychopharmacol 32:1379\u20131384","journal-title":"J Psychopharmacol"},{"key":"1020_CR121","first-page":"879","volume":"371","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Compton WM, Weiss SR (2014) Adverse health effects of marijuana use. N Engl J Med 371:879","journal-title":"N Engl J Med"},{"key":"1020_CR122","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1177\/1352458505070618","volume":"12","author":"DT Wade","year":"2006","unstructured":"Wade DT, Makela PM, House H, Bateman C, Robson P (2006) Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 12:639\u2013645","journal-title":"Mult Scler"},{"key":"1020_CR123","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.neuroscience.2014.07.041","volume":"277","author":"ZY Wang","year":"2014","unstructured":"Wang ZY, McDowell T, Wang P, Alvarez R, Gomez T, Bjorling DE (2014) Activation of CB1 inhibits NGF-induced sensitization of TRPV1 in adult mouse afferent neurons. Neuroscience 277:679\u2013689","journal-title":"Neuroscience"},{"key":"1020_CR124","volume-title":"World Health Organization (WHO), Geneva, Switzerland: WHO","author":"WHO","year":"2018","unstructured":"WHO (2018) World Health Organization (WHO), Geneva, Switzerland: WHO. Fortieth Report, Geneva"},{"key":"1020_CR125","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1089\/can.2019.0052","volume":"5","author":"M Wright","year":"2020","unstructured":"Wright M, di Ciano P, Brands B (2020) Use of cannabidiol for the treatment of anxiety: a short synthesis of pre-clinical and clinical evidence. Cannabis Cannabinoid Res 5:191\u2013196","journal-title":"Cannabis Cannabinoid Res"},{"key":"1020_CR126","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1097\/j.pain.0000000000000680","volume":"157","author":"F Yang","year":"2016","unstructured":"Yang F, Xu Q, Shu B, Tiwari V, He SQ, Vera-Portocarrero LP, Dong X, Linderoth B, Raja SN, Wang Y, Guan Y (2016) Activation of cannabinoid CB1 receptor contributes to suppression of spinal nociceptive transmission and inhibition of mechanical hypersensitivity by A\u03b2-fiber stimulation. Pain 157:2582\u20132593","journal-title":"Pain"},{"key":"1020_CR127","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1111\/bph.12607","volume":"171","author":"S Zoppi","year":"2014","unstructured":"Zoppi S, Madrigal JL, Caso JR, Garc\u00eda-Guti\u00e9rrez MS, Manzanares J, Leza JC, Garc\u00eda-Bueno B (2014) Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice. Br J Pharmacol 171:2814\u20132826","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1020_CR128","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/ijms19030833","volume":"19","author":"S Zou","year":"2018","unstructured":"Zou S, Kumar U (2018) Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci 19(3):833","journal-title":"Int J Mol Sci"},{"key":"1020_CR129","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1590\/S1516-44462008000300015","volume":"30","author":"AW Zuardi","year":"2008","unstructured":"Zuardi AW (2008) Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Braz J Psychiatry 30:271\u2013280","journal-title":"Braz J Psychiatry"},{"key":"1020_CR130","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/026988119300700112","volume":"7","author":"AW Zuardi","year":"1993","unstructured":"Zuardi AW, Cosme RA, Graeff FG, Guimar\u00e3es FS (1993) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7:82\u201388","journal-title":"J Psychopharmacol"},{"key":"1020_CR131","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fphar.2017.00259","volume":"8","author":"AW Zuardi","year":"2017","unstructured":"Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimar\u00e3es FS, Crippa JAS (2017) Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 8:259","journal-title":"Front Pharmacol"},{"key":"1020_CR132","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00432554","volume":"76","author":"AW Zuardi","year":"1982","unstructured":"Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76:245\u2013250","journal-title":"Psychopharmacology"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-022-01020-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-022-01020-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-022-01020-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T03:54:48Z","timestamp":1700798088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-022-01020-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":132,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1020"],"URL":"https:\/\/doi.org\/10.1007\/s10787-022-01020-z","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"2 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are employees and shareholders of Medlab Clinical Ltd. (Sydney, Australia). Medlab Clinical funded the publication costs; however, had no role in the design of the review; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}